Company to Transfer North American Production of Xifaxan and Apriso to Steinbach
Valeant Canada today announced a significant new investment of $8 million into its Steinbach, Manitoba manufacturing plant, growing its role in manufacturing and exporting important health care products.
The announcement was made today at the BIO International Convention in the presence of the Manitoba Deputy Minister of Growth, Enterprise & Trade, Mr. James B. Wilson. The President of the Life Science Association of Manitoba, Mrs. Tracey Maconachie, was also present at the announcement.
Valeant will complete the transfers of the North American production of Xifaxan and Apriso this year, to its Steinbach facility. These transfers support Valeant's commitment to Canada as an anchor manufacturing site.
"Since 2012, Valeant has transferred 27 technologies for manufacture at Steinbach, in addition to investing in major improvements to the site in order to maintain competitiveness at the international level," said Jacques Dessureault, President, Valeant Canada. "It is evidence of our continuing business strategy to grow our Canadian capacity and increase our export sales".
"The entire biosciences ecosystem in Canada benefits when manufacturing increases here" said Andrew Casey, President, BIOTECanada. "Through more applied R&D, such as what is happening at the Steinbach facility, the country benefits from the economic and advanced health technology innovation taking place."
About Valeant's Steinbach facility
With its largest North American manufacturing site located in Steinbach, Manitoba, the company owns and operates a state-of-the-art facility which handles all of Valeant's manufacturing of controlled-release products.
Valeant's Steinbach is a full-service pharmaceutical company engaged in the formulation, clinical testing, registration, manufacturing, sale and promotion of pharmaceutical products utilizing advanced drug-delivery technologies. Each year, the facility produces and packages approximately 1.2 billion tablets or capsules of different kinds of medications which are sold worldwide to treat pain, high blood pressure and depression.
With more than 400 employees, Valeant's world-class facility is one of the southeastern Manitoba city's largest employers. The plant currently operates 24-hours, 5 days a week as well as running limited shifts on the weekends.
About Valeant Canada
Valeant Canada is a subsidiary of Valeant Pharmaceuticals International Inc., a multinational specialty pharmaceutical company that develops, manufactures, and markets a broad range of pharmaceutical products, primarily in the areas of dermatology, eye health, cardio-metabolic, and neurology. More information about Valeant Canada can be found at www.valeantcanada.com.